Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2000 | 12-1999 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 35,817 | 2,390 |
| Receivables | 5,935 | 4,390 |
| Inventories | 3,722 | 2,850 |
| Income taxes - deferred | 514 | N/A |
| Other current assets | 453 | 1,650 |
| TOTAL | $46,920 | $11,280 |
| Non-Current Assets | ||
| PPE Net | 1,716 | 1,560 |
| Other Non-Current Assets | 10,173 | 7,750 |
| TOTAL | $11,889 | $9,310 |
| Total Assets | $58,809 | $20,610 |
| Liabilities | ||
| Current Liabilities | ||
| Short Term Debt | 7 | 790 |
| Accounts payable and accrued liabilities | 2,117 | 1,880 |
| Accrued Expenses | 3,975 | 2,350 |
| Other current liabilities | 268 | 270 |
| TOTAL | $6,368 | $7,500 |
| Non-Current Liabilities | ||
| Long Term Debt | 1 | 5,070 |
| TOTAL | $106 | $5,110 |
| Total Liabilities | $6,474 | $12,620 |
| Shareholders' Equity | ||
| Common Shares | 294 | 100 |
| Retained earnings | -78,380 | -28,370 |
| Other shareholders' equity | -1,810 | 33,970 |
| TOTAL | $52,335 | $7,980 |
| Total Liabilities And Equity | $58,809 | $20,600 |